Drugs / PIEZO-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07671027 | Sep 2026 → Aug 2027 expected | Pseudoatrophoderma colli, cutis laxa, osteoarthritis, knee, skin atrophy | Piezo Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PIEZO-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07671027 ↗ |
| Action | Restore | “aims to restore expression of key proteins in the skin for extracellular matrix rejuvenation” NCT07671027 ↗ |
| Modality | Other / unclassified | “an investigational plasmid DNA biostimulator” NCT07671027 ↗ |
| Route | Other | “PIEZO-101 is administered using an intradermal injection” NCT07671027 ↗ |